MAPT and Alzheimer disease: PET imaging or cerebral spinal fluid (CSF)-measured Aβ and tau is considered the gold standard for the in vivo diagnosis of AD, as recently proposed in the amyloid-tau-neurodegeneration (A/T/N) framework [39].